Blue Cross Blue Shield of Vermont and The Vermont Health Plan
Step Therapy Form
DARAPRIM® (pyrimethamine)

Description: Pyrimethamine is a folic acid antagonist and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and Toxoplasma gondii.

Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans.

The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides.

FDA Indications: Pyrimethamine is indicated in the treatment of toxoplasmosis conjointly with a sulfonamide

Also, indicated in the treatment of acute malaria.

Contraindications Known hypersensitivity to pyrimethamine or to any component of the formulation. Use of the drug is also contraindicated in patients with documented megaloblastic anemia due to folate deficiency.

Reasons for Prior Authorization:
- ☒ Cost
- ☐ Potential for misuse
- ☐ Toxicity

Criteria for Approval:
1. Member has had a 30 day trial and failure of Pyrimethamine/leucovorin which can be provided by Imprimis Pharmaceuticals

A physician can contact Imprimis at 866-551-7195 or logging into http://www.imprimiscares.com

Initial Approvals:

Reasons for Denial of Benefit: Patient does not meet above criteria